Literature DB >> 17698957

Stabilized immune modulatory RNA compounds as agonists of Toll-like receptors 7 and 8.

Tao Lan1, Ekambar R Kandimalla, Dong Yu, Lakshmi Bhagat, Yukui Li, Daqing Wang, Fugang Zhu, Jimmy X Tang, Mallikarjuna R Putta, YanPing Cong, Anthony F Trombino, Tim Sullivan, Sudhir Agrawal.   

Abstract

Viral and synthetic single-stranded RNAs are the ligands for Toll-like receptor (TLR)7 and TLR8. However, single-stranded RNA is rapidly degraded by ubiquitous RNases, and the studies reported to date have used RNA with lipid carriers. To overcome nuclease susceptibility of RNA, we have synthesized several RNAs incorporating a range of chemical modifications. The present study describes one pool of RNA compounds, referred to as stabilized immune modulatory RNA (SIMRA) compounds, in which two RNA segments are attached through their 3' ends. SIMRA compounds showed greater stability in human serum compared with linear RNA and activated human TLR8, but not TLR7, in HEK293 cells without using lipid carriers. Interestingly, another set of SIMRA compounds containing 7-deazaguanosine substituted for natural guanosine activated human TLR7 and TLR8. Additionally, TLR7- and TLR8-activating compounds, but not the compounds that activated only TLR8, stimulated mouse immune cells in vitro and in vivo and produced dose-dependent T helper 1-type cytokines. Both types of compounds activated human peripheral blood mononuclear cells, but only TLR7- and TLR8-activating compounds activated plasmacytoid dendritic cells and produced high levels of IFN-alpha. In monkeys, s.c. administration of both types of SIMRA compounds induced transient changes in peripheral blood monocytes and neutrophils, and activated T lymphocytes, monocytes, and NK cells. Both types of compounds induced IFN-gamma-inducible protein 10, but only the 7-deazaguanosine-containing compound that activated both TLR7 and TLR8 induced IFN-alpha in monkeys. This is a comprehensive study of RNA-based compounds containing structures and synthetic stimulatory motifs in mouse, monkey, and human systems without using lipid carriers.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17698957      PMCID: PMC1959454          DOI: 10.1073/pnas.0706059104

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  28 in total

1.  In vivo application of RNA leads to induction of specific cytotoxic T lymphocytes and antibodies.

Authors:  I Hoerr; R Obst; H G Rammensee; G Jung
Journal:  Eur J Immunol       Date:  2000-01       Impact factor: 5.532

Review 2.  Innate immune recognition.

Authors:  Charles A Janeway; Ruslan Medzhitov
Journal:  Annu Rev Immunol       Date:  2001-10-04       Impact factor: 28.527

3.  'Immunomers'--novel 3'-3'-linked CpG oligodeoxyribonucleotides as potent immunomodulatory agents.

Authors:  Dong Yu; Ekambar R Kandimalla; Lakshmi Bhagat; Jin-Yan Tang; Yanping Cong; Jimmy Tang; Sudhir Agrawal
Journal:  Nucleic Acids Res       Date:  2002-10-15       Impact factor: 16.971

4.  Immunostimulatory RNA oligonucleotides trigger an antigen-specific cytotoxic T-cell and IgG2a response.

Authors:  Carole Bourquin; Laura Schmidt; Veit Hornung; Cornelia Wurzenberger; David Anz; Nadja Sandholzer; Susanne Schreiber; Andreas Voelkl; Gunther Hartmann; Stefan Endres
Journal:  Blood       Date:  2007-04-01       Impact factor: 22.113

5.  Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway.

Authors:  Hiroaki Hemmi; Tsuneyasu Kaisho; Osamu Takeuchi; Shintaro Sato; Hideki Sanjo; Katsuaki Hoshino; Takao Horiuchi; Hideyuki Tomizawa; Kiyoshi Takeda; Shizuo Akira
Journal:  Nat Immunol       Date:  2002-01-22       Impact factor: 25.606

6.  Immune stimulation by a CpG-containing oligodeoxynucleotide is enhanced when encapsulated and delivered in lipid particles.

Authors:  B Mui; S G Raney; S C Semple; M J Hope
Journal:  J Pharmacol Exp Ther       Date:  2001-09       Impact factor: 4.030

7.  Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3.

Authors:  L Alexopoulou; A C Holt; R Medzhitov; R A Flavell
Journal:  Nature       Date:  2001-10-18       Impact factor: 49.962

8.  Molecular basis for the immunostimulatory activity of guanine nucleoside analogs: activation of Toll-like receptor 7.

Authors:  Jongdae Lee; Tsung-Hsien Chuang; Vanessa Redecke; Liping She; Paula M Pitha; Dennis A Carson; Eyal Raz; Howard B Cottam
Journal:  Proc Natl Acad Sci U S A       Date:  2003-05-08       Impact factor: 11.205

9.  Cationic liposome-mediated delivery of siRNAs in adult mice.

Authors:  Mouldy Sioud; Dag R Sørensen
Journal:  Biochem Biophys Res Commun       Date:  2003-12-26       Impact factor: 3.575

10.  A dinucleotide motif in oligonucleotides shows potent immunomodulatory activity and overrides species-specific recognition observed with CpG motif.

Authors:  Ekambar R Kandimalla; Lakshmi Bhagat; Fu-Gang Zhu; Dong Yu; Yan-Ping Cong; Daqing Wang; Jimmy X Tang; Jin-Yan Tang; Cathrine F Knetter; Egil Lien; Sudhir Agrawal
Journal:  Proc Natl Acad Sci U S A       Date:  2003-11-10       Impact factor: 11.205

View more
  29 in total

1.  Ehrlichia chaffeensis induces monocyte inflammatory responses through MyD88, ERK, and NF-κB but not through TRIF, interleukin-1 receptor 1 (IL-1R1)/IL-18R1, or toll-like receptors.

Authors:  Koshiro Miura; Junji Matsuo; M Akhlakur Rahman; Yumi Kumagai; Xin Li; Yasuko Rikihisa
Journal:  Infect Immun       Date:  2011-09-19       Impact factor: 3.441

2.  Nucleoside modifications modulate activation of the protein kinase PKR in an RNA structure-specific manner.

Authors:  Subba Rao Nallagatla; Philip C Bevilacqua
Journal:  RNA       Date:  2008-04-21       Impact factor: 4.942

3.  Lipid-derived nanoparticles for immunostimulatory RNA adjuvant delivery.

Authors:  David N Nguyen; Kerry P Mahon; Ghania Chikh; Phillip Kim; Hattie Chung; Alain P Vicari; Kevin T Love; Michael Goldberg; Steve Chen; Arthur M Krieg; Jianzhu Chen; Robert Langer; Daniel G Anderson
Journal:  Proc Natl Acad Sci U S A       Date:  2012-03-15       Impact factor: 11.205

Review 4.  Targeting Toll-like receptors: emerging therapeutics?

Authors:  Elizabeth J Hennessy; Andrew E Parker; Luke A J O'Neill
Journal:  Nat Rev Drug Discov       Date:  2010-04       Impact factor: 84.694

5.  TLR8 activation and inhibition by guanosine analogs in RNA: Importance of functional groups and chain length.

Authors:  Tiannan Hu; Scott R Suter; Madeline M Mumbleau; Peter A Beal
Journal:  Bioorg Med Chem       Date:  2017-11-11       Impact factor: 3.641

6.  RAGE Enhances TLR Responses through Binding and Internalization of RNA.

Authors:  Damien Bertheloot; Allison L Naumovski; Pia Langhoff; Gabor L Horvath; Tengchuan Jin; Tsan Sam Xiao; Natalio Garbi; Sudhir Agrawal; Roland Kolbeck; Eicke Latz
Journal:  J Immunol       Date:  2016-10-19       Impact factor: 5.422

Review 7.  Targeting pattern recognition receptors in cancer immunotherapy.

Authors:  Nadège Goutagny; Yann Estornes; Uzma Hasan; Serge Lebecque; Christophe Caux
Journal:  Target Oncol       Date:  2012-03-08       Impact factor: 4.493

Review 8.  The pharmacokinetics of Toll-like receptor agonists and the impact on the immune system.

Authors:  Abbi L Engel; Gregory E Holt; Hailing Lu
Journal:  Expert Rev Clin Pharmacol       Date:  2011-03       Impact factor: 5.045

9.  Cutting edge: the UNC93B1 tyrosine-based motif regulates trafficking and TLR responses via separate mechanisms.

Authors:  Karin Pelka; Kshiti Phulphagar; Jana Zimmermann; Rainer Stahl; Jonathan L Schmid-Burgk; Tobias Schmidt; Jan-Hendrik Spille; Larisa I Labzin; Sudhir Agrawal; Ekambar R Kandimalla; Jean-Laurent Casanova; Veit Hornung; Ann Marshak-Rothstein; Stefan Höning; Eicke Latz
Journal:  J Immunol       Date:  2014-09-03       Impact factor: 5.422

10.  Complement receptor 3 influences toll-like receptor 7/8-dependent inflammation: implications for autoimmune diseases characterized by antibody reactivity to ribonucleoproteins.

Authors:  Joanne H Reed; Manish Jain; Kristen Lee; Ekambar R Kandimalla; Mohd Hafeez Faridi; Jill P Buyon; Vineet Gupta; Robert M Clancy
Journal:  J Biol Chem       Date:  2013-02-05       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.